Targeted drug may prolong survival of patients with cervical cancer

March 10, 2014, Wiley

A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.

Nearly half a million new cases of cervical cancer are reported worldwide each year, making it the third most common cancer among females. Despite the widespread use of screening programs and the recent advent of vaccines against , cervical cancer continues to be a significant public health problem.

Cisplatin-based chemoradiation is the standard therapy for locally advanced cervical cancer. Unfortunately, treatment responses are unpredictable and often disappointingly brief. A potentially promising new treatment strategy involves targeting the epithelial growth factor receptor (EGFR), which is frequently overexpressed in cervical cancer. Inhibiting this receptor is known to have antitumor effects against a variety of cancers.

Angélica Nogueira-Rodrigues, MD, PhD, of the Brazilian National Cancer Insitute, and her colleagues designed a phase 2 clinical trial to test the potential of the EFGR inhibitor erlotinib combined with chemoradiation therapy in 36 women with cervical cancer. Median duration of therapy was 77 days and median follow-up time was 59.3 months.

The therapy was well tolerated overall, and 34 patients (94.4 percent) achieved a complete response (meaning the disappearance of all cancerous lesions). After two years, 91.7 percent of women were alive, and 80.6 percent experienced no progression of their disease. After three years, 80 percent of women were alive, and 73.8 percent experienced no disease progression.

"While cervical cancer is a neglected disease and very few clinical trials have been reported in the last 10 years, some groups, including ours, have reported that its biology might be prone to targeted therapy," said Dr. Nogueira-Rodrigues. "To the best of our knowledge, this is the first study to present that a targeted agent has promising activity in the management of locally advanced cervical disease." She added that targeted therapies may be added to the standard treatment for locally advanced if randomized trials confirm the current study's results.

Explore further: Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer "promising"

More information: "Phase II trial of erlotinib combined with cisplatin and radiotherapy in locally advanced cervical cancer." Angélica Nogueira-Rodrigues, Giulliana Moralez, Rachele Grazziotin, Claudio C. Carmo, Isabele A. Small, Flavia V.G. Alves, Marcelo Mamede, Felipe Erlich, Celia Viegas, Sergio A. Triginelli, and Carlos G. Ferreira. Cancer; Published Online: March 10, 2014 DOI: 10.1002/cncr.28471

Related Stories

Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer "promising"

January 15, 2014
(Medical Xpress)—An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of ...

Promising cervical cancer study

February 21, 2014
Research on cervical cancer performed by a physician at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center has been published in the New England Journal of Medicine. The multi-site research ...

HPV vaccination is associated with reduced risk of cervical lesions in Denmark

February 19, 2014
A reduced risk of cervical lesions among Danish girls and women at the population level is associated with use of a quadrivalent HPV vaccine after only six years, according to a new study published February 19 in the Journal ...

Cervical cancer screening and treatment are neglected in low- and middle-income countries

August 13, 2013
While there have been substantial improvements in mortality rates and an increase in access to reproductive health interventions in low- and middle-income countries (LMICs), the global health community is neglecting prevention, ...

France announces 1.5-billion-euro anti-cancer plan

February 4, 2014
French President Francois Hollande on Tuesday announced a 1.5 billion euro ($2 billion) anti-cancer plan aimed at reducing inequalities in treatment of the disease.

Screening helps prevent cervical cancer in older women

January 14, 2014
New research from Queen Mary University of London reveals women over the age of 50 who don't attend cervical screening are four times more likely to be diagnosed with cervical cancer in later life.

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.